b2d150468f5f48b58f5b4270134e60fa

Aug 4, 2026

Pathos AI Signs Two Major Breast Cancer Drug Licensing Deals Worth Over $2B, Plans $3B Series E

Pathos AI announced two significant licensing agreements for breast cancer treatments: a $2.2 billion deal with China's Alphamab Oncology for bispecific ADC JSKN016 targeting triple-negative breast cancer, and a co-exclusive agreement with AstraZeneca for ERα degrader AZD4241 for ER-positive breast cancer. The company is reportedly planning to raise a Series E round at a $3 billion valuation.

Aug 4, 20268 sources

AstraZeneca stories

Pathos AI Signs Two Major Breast Cancer Drug Licensing Deals Worth Over $2B, Plans $3B Series E

AstraZeneca in talks with Bristol Myers Squibb on $400 billion megadeal

AstraZeneca reports mixed late-stage trial results with Ultomiris failure and Claudin 18.2 ADC success

AstraZeneca's Sonesitatug Vedotin Shows Significant Survival Improvement in Phase III Gastric Cancer Trial

European Commission Approves AstraZeneca's Etcamah for ER-Positive Breast Cancer with ESR1 Mutations

AstraZeneca Acquires Lung Cancer Drug from China's Dizal Pharmaceutical in $1.5 Billion Deal

AstraZeneca and Ionis' heart disease drug Wainua fails pivotal trial, shares plunge

AstraZeneca and Daiichi Sankyo Near UK Pricing Agreement for Breast Cancer Drug Enhertu

AstraZeneca's experimental obesity pill achieves 10.5% weight loss in phase II trial

AstraZeneca's Imfinzi-Enfortumab Vedotin Combination Shows Historic Survival Gains in Bladder Cancer Trial

AstraZeneca Commits $405M to UK Expansion Following US-UK Pharma Deal

FDA Requests Additional Liver Injury Data on Eli Lilly Obesity Pill Foundayo

Related entities

Featured Stories

OpenAI pauses development of Astra AI model over critical cybersecurity capability concerns